PATENT CLAIM ANALYSIS

Application Number: 15906745
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "210180"]

Abstract:
Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Claim (Index 45):
A method of treating a disease or condition selected from the group consisting of idiopathic pulmonary fibrosis, diabetic nephropathy, focal segmental glomerulosclerosis, chronic kidney disease, nonalcoholic steatohepatitis, primary biliary cholangitis, primary sclerosing cholangitis, solid tumors, hematological tumors, organ transplant, Alport syndrome, interstitial lung disease, radiation-induced fibrosis, bleomycin-induced fibrosis, asbestos-induced fibrosis, flu-induced fibrosis, coagulation-induced fibrosis, vascular injury-induced fibrosis, aortic stenosis, and cardiac fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1 .

Metadata:
- Claim Count in Document: 38.0
- Percentile: 88.0
- Lexical Diversity: 1.15
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14448941', '12728153', '15612030', '12975900', '13646143']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7500252699125106
- 35 USC 102 Novelty (BERT): 0.5263063873564165
- Combined Prediction Score: 0.7276533816569012
- Mean Citation Score: 308.308034
- Max Citation Score: 312.28763
- Similarity Product: 207.17861077112136

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test